Nuvectis Pharma Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company, has announced the final clinical data update from the Phase 1b study of NXP800 in recurrent, platinum resistant, ARID1a-mutated ovarian cancer. The study, which involved 13 patients, reported 2 partial responses and 3 stable diseases. Thrombocytopenia was managed through an intermittent dosing schedule. While the data suggests biological activity of NXP800, the company has decided to prioritize the advancement of NXP900 due to resource considerations. Additionally, Nuvectis has completed the Phase 1a dose escalation study for NXP900, which assessed its safety, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. The study found that systemic exposure to NXP900 increased with higher doses, with a robust pharmacodynamic response observed at doses of 150 mg/day and higher. The initiation of the Phase 1b program for NXP900, aimed at evaluating its safety and efficacy as a single agent and in combination with other anti-cancer agents, is expected in the coming weeks. The final data from the Phase 1a study is anticipated to be presented at a future medical or scientific conference.